Former Obama Drug Official Sued In Addiction Fraud Lawsuit : No charges filed !!

Former Obama Drug Official Sued In Addiction Fraud Lawsuit

https://www.newsy.com/stories/former-obama-administration-official-sued-in-fraud-lawsuit/

Thomas McLellan, who worked in the drug czar’s office from 2009 to 2012, is accused of helping a fraudulent rehab center.

A former White House official high up in the drug czar’s office is named in a new federal lawsuit, accusing him of fraud in the drug rehabilitation industry and using his contacts to enrich his family.

Thomas McLellan served as deputy director of the Office of National Drug Control Policy from 2009 to 2012 in the Obama administration. The lawsuit is accusing McLellan and his son, Andrew, of holding on to millions of dollars from what it calls a “criminal, sham” addiction treatment center outside of Philadelphia.

The younger Andrew McLellan became a part owner and board manager of Liberation Way in 2015 after investing $300,000 that he was given by his father, according to the lawsuit. It also alleges that in 2016, Thomas McLellan offered to reach out “to his higher up contacts” that he used to work with to fend off an audit from an insurer that had developed “significant concerns” about Liberation’s activity. A year later in December 2017, McLellan’s son allegedly cashed out a nearly $5 million position in the company. And Newsy discovered county real estate records that show just one month later, he purchased this home in the Philadelphia suburbs for $2.9 million. On Zillow, the home is described as the “crown jewel” of its area, complete with a pool and seven bathrooms.  By March of this year, state and federal officials charged Liberation’s remaining owners with an elaborate insurance fraud scheme — alleging the company and its officers were getting kickbacks related to blood and urine screenings, and billing for medically unnecessary treatments. The company collapsed following the criminal charges of the remaining owners.

“These individuals profited off of the pain of these individuals who were battling addiction,” Pennsylvania Attorney General Josh Shapiro said in his announcement of the charges.

Neither McLellan was criminally charged. But now the key lender in the purchase of Liberation Way — Oxford Finance — is suing in civil court to get its money back, saying it lent the money based on fraudulent information from the owners, and it would therefore be “unjust” if the McLellans got to keep their millions. 

“They were defrauded into making the loan, so from an equitable standpoint, people shouldn’t make money off their fraud,” said Andrew Rothermel, who was appointed CEO of Liberation after investors learned about the alleged fraud. 

Neither the McLellans nor their attorneys returned Newsy’s multiple requests for comment. 

Advocates say the alleged actions of the former White House official and his son highlight larger concerns about what can happen when the little-regulated drug treatment industry doesn’t put patients before profits. 

“What that does to the psyche of someone trying to work a program, work on his recovery, it’s shattering. It’s mentally and emotionally shattering them,” said Maureen Kielian of Southeast Florida Recovery Advocates. 

Rep. Sewell’s ‘NOPAIN’ Bill Is Really ‘NO-BRAIN’

Rep. Sewell’s ‘NOPAIN’ Bill Is Really ‘NO-BRAIN’

https://www.acsh.org/news/2019/12/09/rep-sewells-nopain-bill-really-no-brain-14442

Representatives Terri Sewell (AL) and David McKinley (WV) are trying to push through a new law ensuring that Medicare patients have equal access to “non-opioid” therapies after surgery. If they succeed then Medicare recipients will have earned the right to suffer along with the rest of us. Brilliant.

Despite a decade of indisputable evidence that we are not having an “opioid crisis.” but rather a “heroin/fentanyl crisis” you might think that people might start to figure this out and act accordingly.

No such luck. Legislators, policymakers, and other assorted ignorant and/or self-serving busybodies continue to play darts in a dark room with an Ikea bag over their heads. They cannot or will not see what is right in front of their collective faces – that 1) legitimate medical use of analgesics only rarely leads to addiction, and 2) more restrictions placed prescription analgesics has only resulted in more overdose deaths as well as ghoulish suffering of people in pain who need medications that they can no longer get. Yes, it is that obvious, but the false narrative that overprescription of painkilling drugs is responsible for today’s overdose deaths is like the Energizer Bunny – it just won’t quit.

No, I don’t have any idea why the Andrews Sisters are in there. They never sang the stupid song. Photo: The Growler

And the nonsense keeps coming, thanks to a mindless and misguided legislative effort that is making its way through the House of Representatives.

On the surface, a seriously awful bill that is being put forward by Rep. Terri Sewell (1), a four-term congresswoman in Alabama, would seem to be just more of the same – demonization of opioid analgesics to accomplish… whatever… and the usual blather about American deaths and addiction. But this one’s a bit different because of unintended irony.

Here’s a section of the November press release issued by Rep. Sewell’s office (emphasis mine):

Specifically, the bill would address payment disincentives for practitioners to prescribe non-opioid treatment alternatives in surgical settings by requiring CMS to place non-opioid treatments on par with other separately paid drugs and devices in Medicare Part B.

Rep. Sewell’s bill is an attempt to “level the playing field” by ensuring that Medicare patients will have “access to non-opioid treatments for pain.” In other words, Medicare patients will now have the same “right” to suffer as those who have private insurance by being forced to try the same unproven and ineffective “treatments”. Perhaps they can, as former Attorney General and permanent ignoramus Jeff Sessions said in 2018, “just take some aspirin sometimes and tough it out a little.” (See ‘Let Them Eat Aspirin’ – Jeff Sessions’ Painfully Ignorant Remarks)

And why? For a really stupid reason:

“Non-opioid treatments and therapies can be successful in replacing, delaying or reducing the use of opioids to treat post-surgical pain, and reduce the risk of opioid addiction.”

No, that’s just plain wrong. Let’s hear from some people who actually know what they’re talking about. Like ACSH advisor Dr. Dan Laird:

“Though we want to minimize opioid use when we can, the risk of opioid misuse, abuse, and addiction is low in post surgical patients.  Unnecessary hysteria and anti-opioid zealotry harm patients;  all medications have dangerous side effects but the overall benefit of opioids for post-surgical pain far outweighs the risk.”

Danial Laird, MD, JD 12/7/19 

or ACSH advisor Dr. Jeff Singer:

“The likelihood of addiction, defined as compulsive use despite negative consequences, developing after taking just a few days worth of prescription opioids after leaving the hospital, is close to zero–as also the case with regard to physical dependence.”

Dr. Jeff Singer, 12/9/19

Or Dr. Thomas Kline, a specialist in geriatric medicine and long-time defender of pain patient rights:

“If the patient has had opiates before, the chance of addiction after surgery is zero. If not, that chance becomes 4 in 1,000 after age 12 and 2 in 1000 after age 20, largely due to genetic factors that control opioid addiction. In a recent study of 1,000 people given opioids following urological surgery two people became “street addicted.”

If Rep. Sewell really thinks that funding CMS to pay for non-opioid post-op treatments for the purpose of preventing addiction she is deluding herself. 

Let’s take a look at some more of the bill (emphasis mine).

Congress finds the following:

(1) The United States is undergoing an epidemic of addiction and deaths caused by prescription drug overdoses. According to the [CDC], opioids are the main driver of drug overdose deaths accounting for 47,600 overdose deaths in 2017. Every day, over 130 people die in the United States from opioid overdoses.

I can’t believe that after all these years of refuting this crap I have to keep doing it. Yes, opioids are the main driver of overdose deaths, but not the legal prescriptions that Rep. Sewell is trying to restrict:

Let’s look at those 47,600 deaths (below). If you didn’t know any better this proposed legislation would lead you to believe that Vicodin is wiping out hoards of Americans. This is false. As I (and others) have written many times, the real killer is illicit fentanyl and its analogs (this is confusingly referred to as “synthetic opioids other than methadone” in Table 1 below). The fentanyls (illicit fentanyl and analogs) were involved in 28,466 deaths (60% of the total) in 2017 followed by heroin 15,482 (32%) of the overdose deaths. “Natural and semisynthetic opioids,” a confusing and ambiguous term for prescription analgesics were involved in 15,482 deaths (30%) (1,2).

Now let’s restate that portion of the bill so that it is factually correct: “Illegal opioids, mainly fentanyl and its analogs, and heroin are the main drivers of drug overdose deaths accounting for a huge majority of the 47,600 overdose deaths in 2017.

Table 1: Opioid overdose deaths (2014-2017) by opioid category. Note the massive increase in fentanyl-related deaths between 2014-2017. Source: CDC

If that’s not bad enough…

Research shows that patients receiving an opioid prescription after short-stay surgeries have a 44% increased risk of opioid use.

Please! Stop! This is making my hair hurt. People who get opioids after surgery are more likely to use them than people who don’t get opioids after surgery??? Seriously? Tell me that this isn’t conceptually identical to…

“People who lose their legs in auto accidents are less likely to subsequently develop athlete’s foot than those who do not.”

Rep. Sewell did not come up with this masterpiece on her own. She had help from Rep. David McKinley (West Virginia). Together they introduced the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act (H.R. 5172). McKinley’s incisive knowledge of medicine must certainly come from his former career… as an engineer:

“Our bill would ensure that CMS does not disincentivize the use of innovative non-opioid drugs and devices to treat and manage pain. While pain management for all patients should be handled individually, opioids should not be the first or only option given.”

Rep. David McKinley, B.S. Civil Engineering, 11/19/19 

Sorry, Rep. McKinley. Whether opioids should or should not be given to post-surgical patients is something you know nothing about and is none of your business. Would you want Dr. Oz to redesign Hoover Dam?

 

David Pezzula: this time the pain was too difficult, and he died by suicide on Friday morning, December 6, 2019

David Pezzula will always be remembered for his sharp wit and courage during difficult times. Unfortunately,

this time the pain was too difficult, and David died by suicide on Friday morning, December 6, 2019.

David, 52, was born on May 26, 1967 in Pittsburgh, PA. He was lovingly adopted by Dominic and Dorothy Pezzula, who both preceded him in death. David leaves behind a brother, Daniel Pezzula as well as many nieces and nephews whom he loved very much. He also leaves behind his beloved dog, Cooper, who was his entire world, and SO MANY friends that loved him more than he knew. We will all miss him beyond measure.

David was a prolific writer/blogger and was known for his sarcasm and severe distaste for our current political situation. He was unabashedly honest and a source of constant entertainment to his many friends. He would do anything to help out his fellow man and had a heart of gold. As evidence of his generosity, his final gift was one of organ donation.

At his request, no service will be held.

If you are in crisis, please call the National Suicide Prevention Lifeline at 1-800-273-TALK (8255) or contact the Crisis Text Line by texting TALK to 741741.

Medicare Advantage plans: received an estimated $6.7 billion in 2017 after adding diagnoses to patients’ files that were not supported by their medical records

U.S. watchdog finds $6.7 billion in questionable Medicare payments to insurers

https://www.reuters.com/article/us-usa-health-medicare-payments/u-s-watchdog-finds-6-7-billion-in-questionable-medicare-payments-to-insurers-idUSKBN1YG0YD

A U.S. government watchdog is raising fresh concerns that health insurers are exaggerating how sick Medicare patients are, receiving billions of dollars in improper payments as a result.

Health insurers selling

Medicare Advantage plans to seniors and the disabled received an estimated $6.7 billion in 2017 after adding diagnoses to patients’ files that were not supported by their medical records,

according to a report released on Thursday by the U.S. Health and Human Services (HHS) Inspector General’s Office.

Inspectors found that Medicare Advantage insurers had added diagnoses for diabetes, heart disease and other conditions in 99.3% of chart reviews of patient information, even though they did not appear in records from doctors, hospitals or other medical providers. Insurers deleted incorrect diagnoses less than 1% of the time, they found.

The additional diagnoses boosted government payments to insurers by an estimated $6.9 billion, while the deleted information trimmed payouts by nearly $200 million, producing a net benefit of $6.7 billion for the companies.

“We could not see any services with the diagnosis and that raised a number of concerns,” Linda Ragone, a regional inspector general in Philadelphia and co-author of the report, said in a phone interview. “There is a vulnerability here that needs to be addressed.”

The report highlighted a group of 4,616 Medicare Advantage enrollees for whom insurers added a diagnosis that resulted in a higher payment, even though there was no record of the person receiving any medical services during the year under review.

Medicare Advantage plans are privately-run alternatives to traditional Medicare. They served 22 million people – or 1 in 3 of those eligible for the government healthcare program – at a cost of $210 billion in 2018.

The report did not identify specific insurers. UnitedHealth Group Inc (UNH.N), Humana Inc (HUM.N) and CVS Health Corp (CVS.N) through its ownership of Aetna, are among the biggest sellers of Medicare Advantage plans. Together, the three companies have 54% of the market, according to the Kaiser Family Foundation.

America’s Health Insurance Plans (AHIP), an industry trade group, said the rate of improper payments in the Medicare Advantage program has been decreasing.

“Everyone agrees that Medicare Advantage payments must be fair and accurate, and we continue to work with (Medicare) to improve payment accuracy,” said AHIP spokeswoman Kristine Grow.

The U.S. government pays Medicare Advantage insurers based on a risk score for each enrollee. The formula pays more for sicker patients, creating a financial incentive for insurers to inflate risk scores.

The U.S. Centers for Medicare and Medicaid Services (CMS) should be doing more to prevent insurers from exploiting this vulnerability, the inspector general said.

In a Nov. 1 letter to the inspector general’s office cited in the report, CMS challenged the $6.7 billion estimate of payments linked to chart reviews as too high. The agency agreed with the report’s recommendations for increased oversight and audits.

CMS in a statement said it is “committed to ensuring that Medicare Advantage plans submit accurate information to CMS so that payments to plans are appropriate.”

Prior to these findings, Medicare estimated it had made $40 billion in overpayments to insurers from 2013 to 2016 due to diagnoses submitted by health plans not supported by medical records.

Our judicial system at its finest: Strip-search policy halted after 8-year-old reportedly told to get naked at Virginia prison

Image; Buckingham Correctional Center in Dillwyn

Strip-search policy halted after 8-year-old reportedly told to get naked at Virginia prison

https://www.nbcnews.com/news/us-news/strip-search-policy-halted-after-8-year-old-reportedly-told-n1097551

The girl was visiting her father when she was led to believe that if she didn’t remove her clothes she wouldn’t be able to see him, according to reports.

Virginia’s governor on Friday ordered the suspension of a Department of Corrections policy after an 8-year-old was reportedly strip-searched when attempting to visit her father in prison last month.

“I am deeply disturbed by these reports — not just as Governor, but as a pediatrician and a dad,” Gov. Ralph Northam, a Democrat, tweeted Friday.

He said that he had directed the secretary of public safety and homeland security “to suspend this policy while the Department conducts an immediate investigation and review of their procedures.”

On Nov. 24, a minor was strip-searched at the Buckingham Correctional Center in Dillwyn by a Department of Corrections employee, the department’s communications director confirmed in a statement.

The Virginian-Pilot newspaper reported that the minor was an 8-year-old girl, accompanied by her father’s girlfriend, and that they were led to believe that refusing the search would result in the girl’s not being allowed to see her father.

Lisa Kinney, the Corrections Department’s communications director, said in a statement that the strip search violated policy, as the staff member who approved it did not have that authority. She called it “deeply troubling” and said it “represents a breach in our protocol.”

“We sincerely apologize to this child and her family,” Kinney said, adding that the department is taking immediate disciplinary action against the person responsible.

The girl’s mother told The Virginian-Pilot that her daughter “was traumatized.”

Both the girl and her father’s girlfriend were made to remove all their clothes and searched, and their car was examined before they were allowed to have a non-contact visit with the child’s father, The Virginian-Pilot reported. No contraband was found.

The girlfriend told the newspaper that the search was ordered after a dog singled her out and that guards initially said the child would not need to be searched but reversed the decision after consulting with a captain.

The girl’s mother plans on filing a lawsuit, the newspaper reported.

The American Civil Liberties Union of Virginia tweeted that Northam was right to suspend the policy.

“We’re pleased that the government is taking steps to protect children from invasive, humiliating strip searches so that this never happens again to another child,” the civil liberties group said.

Dillwyn is a town of around 500 around 35 miles south of Charlottesville.

ask to share – study on MJ

ask to share – study on MJ

Hello Steve, My name is Jordan and I am a research coordinator at the University of Florida. We have a medical marijuana study that is seeking participants over the age of 18 to determine the short and long term effects. I was hoping you would be willing to post the following text and content in your group on behalf of the study team. This content is UF IRB-approved so please do not alter the content. If you, or any of the group members, have questions about the trial or research in general at UF, please have them contact Jordan at (352)448-6718 or MMstudy@PHHP.ufl.edu . Thank you so much!

Researchers at UF are researching the short and long term effects of medical marijuana. If you are 18 years old or older and plan to start medical marijuana for chronic pain, you may be eligible to participate. Compensation provided. Visit the study website to find out more and to see if you qualify: http://bit.ly/MMPainStudy

 

Importing Drugs from Canada is a Flawed “Solution” for Failures in the U.S.

Importing Drugs from Canada is a Flawed “Solution” for Failures in the U.S.

https://pharmacistactivist.com/2019/December_2019.shtml

Prices in the United States for many medications, primarily generic products, are reasonable and even inexpensive considering their value in maintaining and improving health. HOWEVER, the prices for many other medications are excessive and unjustifiable.

It is the pharmaceutical companies that establish the initial list prices for these drugs, but health insurance companies and pharmacy benefit managers also extract large profits from the continued worsening of the drug pricing debacle.

It is ironic that these industries take turns blaming each other for the high costs of drugs while, at the same time, all of them are being further enriched by the secretive and cyclical process in which they continue to increase the prices of drugs. The victims of this “system” are patients who often can’t afford the medications, our society that must assume the financial burden for excessive drug prices, and the pharmacies that are not adequately compensated for their important role in the distribution and appropriate use of medications.

The recognition of these problems is not new. Indeed, the outrage, rhetoric, and debate regarding drug prices have continued for decades, but what has been accomplished? In a word, “NOTHING!” The financial interests, bureaucracy, politics, and lobbying of those who might lose a fraction of their riches have prevented any progress in developing better drug pricing, distribution, and availability strategies.

Because of policies and controls on drug prices that have been established in Canada, many drugs are available at much lower prices there than in the U.S. Approximately 15 years ago, there was strong activity on the part of patients and others in the U.S. to obtain drugs at lower prices from pharmacies in Canada. Although some were successful in this effort, there were also negative ramifications and, for the most part, this strategy failed. One might think that relatively recent experience would still be fresh in our memories. However, once again, some state and national government officials are actively developing plans to facilitate importation of drugs from Canada because we have failed to establish equitable drug pricing strategies in this country. There is a saying that those who ignore history are destined to repeat it. Importation of drugs from Canada was a flawed and failed strategy 15 years ago, and it will fail again now.

The importation of drugs from Canada is not only an unworkable and ineffective strategy, but it is also extremely unfair to inflict certain of the consequences of the drug pricing and distribution failures in the U.S. on our neighboring country. The population of Canada is far smaller than that of the U.S. and the supplies of medications in that country are also correspondingly smaller. If large quantities of certain individual or classes of medications were imported by the U.S. from Canada, this could create havoc in the supply and availability of these medications in Canada. As just one of the many potentially negative consequences of significantly expanded importation of drugs, we are not close to addressing the problems of shortages of important medications in the U.S., and it is inappropriate to burden our neighbor with the risk of consequences resulting from failures in this country to establish an adequate and equitable drug pricing and distribution system. These challenges originated in the U.S., and it is up to the citizens and government of the U.S. to resolve them in this country.

There are concepts and strategies that can greatly improve the affordability of drugs and the quality and effectiveness of the drug distribution system in the U.S. Although they are beyond the scope of this commentary, such strategies are identified in previous editorials in The Pharmacist Activist. However, the courage, will, and determination to take action are essential!

Daniel A. Hussar
danandsue3@verizon.net

FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug

FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug

https://www.fda.gov/news-events/press-announcements/fda-issues-warning-letter-not-including-most-serious-risks-advertisement-medication-assisted

The U.S. Food and Drug Administration today posted a warning letter to Alkermes, Inc. of Massachusetts, for misbranding the drug Vivitrol (an extended-release injection formulation of naltrexone) by omitting warnings about the most serious risks associated with the drug from promotional materials. Vivitrol is approved for the prevention of relapse to opioid dependence, following opioid detoxification and should be part of a comprehensive management program that includes psychosocial support. Known as medication-assisted treatment, the use of medications like Vivitrol, in combination with counseling and behavioral therapies, is effective in the treatment of opioid use disorder (OUD) and can help some people to sustain recovery. The warning letter was issued in relation to a print advertisement about Vivitrol. While the print advertisement contains claims and representations about the drug’s benefits, it fails to adequately communicate important warnings and precautions listed in the product labeling, including vulnerability to opioid overdose, a potentially fatal risk.

“One way the FDA protects the public health is by ensuring that prescription drug information disseminated by drug sponsors is truthful, balanced and accurately communicated. We do this by reviewing prescription drug advertising and promotional labeling to ensure that the information contained in these promotional materials is not false or misleading,” said Thomas Abrams, director of the FDA’s Office of Prescription Drug Promotion in the FDA’s Center for Drug Evaluation and Research. “Vivitrol is being promoted in a way that does not adequately present important risk information in a truthful and non-misleading manner. This is concerning from a public health perspective because of the potential for fatal opioid overdose in this vulnerable patient population.”

The FDA is requesting the company immediately cease advertising practices that misbrand Vivitrol. In addition, because the violations described in the warning letter are serious, the FDA is also requesting the company include a comprehensive plan of action to disseminate truthful, non-misleading and complete corrective messages about the issues discussed in this letter to the audience(s) that received the violative promotional materials.

Specifically, the labeling states that after opioid detoxification, patients are likely to have reduced tolerance to opioids. For approximately 28 days after administration, Vivitrol is designed to block the effect (known as blockade) of an opioid. As the blockade wanes and eventually dissipates completely, patients who have been treated with Vivitrol may respond to lower doses of opioids than previously used. Therefore, if a patient uses opioids at the same dose they previously used, after taking Vivitrol and as the blockade wanes or after missing a dose or discontinuing treatment, it could result in an opioid overdose. There is also the possibility that a patient who is treated with Vivitrol could overcome the opioid blockade effect of Vivitrol. The print advertisement about Vivitrol also omits other important warnings and precautions including the risk of injection site reactions and other common adverse reactions associated with the use of drug. The FDA has requested that Alkermes, Inc. provide a written response to the warning letter to the FDA by Dec. 16.

The warning letter posted today reflects the agency’s commitment to protect the public health by ensuring that prescription drug information is truthful, balanced and accurately communicated as well as the agency’s focus on addressing the opioid crisis, which remains one of the FDA’s top public health priorities. The FDA continues to look at ways to facilitate treatment options to address OUD as a chronic disease with long-lasting effects. There are three drugs approved by the FDA for the treatment of opioid dependence: buprenorphine, methadone and naltrexone. All three of these treatments have been demonstrated to be safe and effective in combination with counseling and psychosocial support.

Health care professionals and consumers should report any adverse events related to these and other drugs to the FDA’s MedWatch Adverse Event Reporting program. To file a report, use the MedWatch Online Voluntary Reporting Form. The FDA monitors these reports and takes appropriate action necessary to ensure the safety of medical products in the marketplace.

The Bad Ad Program is administered by the agency’s Office of Prescription Drug Promotion in the Center for Drug Evaluation and Research. The program’s goal is to help raise awareness among health care professionals about misleading prescription drug promotion and provide them with an easy way to report this activity to the agency. To report potentially false or misleading promotion, health care professionals can send an email to badad@fda.gov or call 855-RX-BADAD.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Four in five pharmacists at high risk of burnout; many reconsider career, survey reveals

Four in five pharmacists at high risk of burnout; many reconsider career, survey reveals

https://www.pharmacy.biz/four-in-five-pharmacists-at-high-risk-of-burnout-many-reconsider-career-survey-reveals/

A new survey has revealed that 80 per cent pharmacists are at high or very high risk of burnout because of exhaustion, with over half of them thinking of a career switch.

The survey conducted by the Royal Pharmaceutical Society (RPS) and Pharmacist Support details the shocking impact of workplace pressures on pharmacists’ mental health.

Nearly three-quarters of the pharmacists said their training or working life has had an impact on their mental health and well being at some point.

More worryingly, some 44 per cent are concerned about potentially making mistakes or providing poor quality service to their patients.

“It’s incredibly tough in frontline practice right now. Demands are increasing and resources are scarce. This is not specific to one sector but impacts pharmacists wherever they work,” said Sandra Gidley, RPS President.

Gidley repeated the organization’s call for equal access to an NHS-funded support service for all pharmacists. At present, only the pharmacists employed directly by the NHS get access to help.

“The Government must address this as a matter of urgency. The NHS is at risk of creating workforce inequalities by providing support service for some staff and not others,” she said.

Responding to the survey, one in five pharmacists each quoted lack of support staff and unrealistic expectations from their manager or organization as the key reason for workplace pressures.

Commenting on the research results, Danielle Hunt, Pharmacists Support Chief Executive said the charity will work with RPS to find more ways to provide funded support.

“At Pharmacist Support, we hear from people every day struggling to deal with the pressures faced at work, so sadly we are not surprised by the statistics around stress and burnout revealed through this survey. Unfortunately for some, by the time they reach out for help, they have already reached crisis point,” Hunt said.

RPS and Pharmacists Support said the organizations will use the evidence to campaign for NHS-funded well being support for all pharmacists.

The organizations will also publish a more detailed analysis in Spring 2020 to inform a round table with the NHS, government, employers and others to identify solutions.

According to the statement made in the article “mistakes” are separate and distinct from “poor service”. Getting healthcare workers to continuously functions at ABOVE 100% is most certainly a formula for mistakes and poor service.  Could those two issues cause some pts to have poor outcomes ?  This article appears to be from England, but the USA is having the same problems.. to few healthcare dollars to provide proper staffing and proper care for pts.

 

Apparently Express Scripts (PBM) is trying to eliminate independent pharmacies by “hook or crook”

Apparently Express Scripts (PBM) is trying to eliminate independent pharmacies by “hook or crook”